Search results
Author(s):
Roland Schmieder
,
Michel Burnier
,
Cara East
,
et al
Added:
1 year ago
Author(s):
Felix Mahfoud
Added:
1 year ago
In this short late-breaking interview, Prof Felix Mahfoud (Saarland University Hospital, DE) discusses the 3-year efficacy outcomes of the SPYRAL HTN-ON MED Pilot Study (NCT02439775). The global clinical study, presented at ACC.22, tested the long-term effect of renal denervation (Symplicity Spyral™ multi-electrode renal denervation system, Medtronic Vascular) on blood pressure reduction in…
View more
Author(s):
Purvi Parwani
Added:
4 months ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac…
View more
Catheter-based Renal Denervation
Author(s):
Philipp Lurz
,
Karl Fengler
Added:
3 years ago
Article
Author(s):
Felix Mahfoud
Added:
2 years ago
In this video, Dr Felix Mahfoud (Saarland University Hospital, Hamburg, DE) discusses the use of the Win Ratio Methodology when applied to the Global SYMPLICITY Study. This registry consisted of the largest followed population of real-world patients with hypertension treated with renal denervation.
Questions:
What is the rationale behind this study?
What is the design, patient cohort and…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
3 days ago
What’s hot at ACC.24?Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24,…
View more
Author(s):
Ajay J Kirtane
,
Harriette Van Spall
Added:
2 years ago
Dr Ajay Kirtane (Columbia University Medical Center, New York, NY, US) joins host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) to discuss the findings from the Randomized Sham-controlled RADIANCE-HTN TRIO Trial.
The studyassessed the efficacy and safety of endovascular ultrasound renal denervation in patients with hypertension resistant to three or more antihypertensive…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Stay updated on the AHA 22 late-breaking data!
In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions.
What are the key take-aways from AHA 22? What are the most promising findings? How should we understand…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
In this dynamic late-breaking science preview Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most anticipated trials of the AHA Scientific Sessions.
What late-breaking trials should we look out for? Which results are likely to impact your practice? What are the considerations and challenges?
Trials covered in detail include:
37s:…
View more
Author(s):
Katrina Mountfort
Added:
3 years ago
Hypertension is one of the most important public health problems of the 21st century, with a global prevalence of around 30 %.1 In 2010, it accounted for 7.5 million deaths worldwide, representing 12.8 % of the global total.2 Furthermore, its prevalence is projected to rise to 1.5 billion hypertensive patients in 2025.3 Despite the availability of numerous safe and effective antihypertensive…
View more